Episode
Ep192: Kate Haviland on Following the Science to Precision Immunology
- Published
- Jan 8, 2026
- Duration seconds
- 5166
- Processing state
not_requested- Canonical source
- https://soundcloud.com/longrunpodcast/longrun_ep192
Actions
POST https://stenobird.com/v1/public/podcasts/the-long-run-with-luke-timmerman-1124799/episodes/ep192-kate-haviland-on-following-the-science-to-precision-immunology/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-long-run-with-luke-timmerman-1124799/ep192-kate-haviland-on-following-the-science-to-precision-immunology.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.